UBS O'Connor’s Vir Biotechnology VIR Stock Holding History

UBS O'Connor’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-38,000	Closed	-$356K	–	608
2023 Q3	$356K	Buy	+38,000	New	+$542K	0.01%	425

Other funds holding VIR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

UBS O'Connor's VIR Position: Q4 2023 in Review

UBS O'Connor sold out of Vir Biotechnology (VIR) in Q4 2023, closing a stake of 38,000 shares — an estimated $356K sold.

UBS O'Connor first reported a position in VIR in Q3 2023 and held it in 1 quarter. The position peaked at $356K in Q3 2023. 206 funds tracked by Wall St. Rank hold VIR as of Q4 2023.

UBS O'Connor reported no remaining Vir Biotechnology position as of Q4 2023 after selling out during the quarter.
UBS O'Connor sold 38,000 Vir Biotechnology shares in Q4 2023, an estimated $356K.
UBS O'Connor first reported a position in Vir Biotechnology in Q3 2023 and held it in 1 quarter.
UBS O'Connor's Vir Biotechnology position peaked at $356K in Q3 2023.
206 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2023.

Based on UBS O'Connor's 13F filing for Q4 2023, filed 14 Feb 2024.